Evidence map›Paper›PMID 32658183›Full record

ArticleJournal of visualized experiments : JoVE2020

Monitoring Cancer Cell Invasion and T-Cell Cytotoxicity in 3D Culture.

Yuan-Na Lin, Apsra Nasir, Sharon Camacho, Deborah L Berry, Marcel O Schmidt, Gray W Pearson, Anna T Riegel, Anton Wellstein

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. GLS1 Orchestrates Exosome-Mediated Tumor-Endothelial Communication to Facilitate Angiogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuan-Na LinLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Apsra NasirLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Sharon CamachoLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Deborah L BerryLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Marcel O SchmidtLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Gray W PearsonLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Anna T RiegelLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University.
Anton WellsteinLombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University; wellstea@georgetown.edu.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitorsR01CA231291 · NCI · GEORGETOWN UNIVERSITY · PI ATKINS, MICHAEL BENJAMIN, WELLSTEIN, ANTON · 2018 to 2022
$2.6M
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast CancerR01CA205632 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2016 to 2020
$2.3M
DEFINING HOW COOPERATION BETWEEN TUMOR SUBPOPULATIONS PROMOTES TUMOR PROGRESSIONR01CA218670 · NCI · GEORGETOWN UNIVERSITY · PI PEARSON, GRAY W · 2017 to 2021
$1.8M
Investigating Breast Cancer Collective InvasionR01CA155241 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEARSON, GRAY W · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA155241NCI NIH HHS R01 CA205632NCI NIH HHS R01 CA218670NCI NIH HHS R01 CA231291
6 · The paper itself

Abstract

Significant progress has been made in treating cancer with immunotherapy, although a large number of cancers remain resistant to treatment. A limited number of assays allow for direct monitoring and mechanistic insights into the interactions between tumor and immune cells, amongst which, T-cells play a significant role in executing the cytotoxic response of the adaptive immune system to cancer cells. Most assays are based on two-dimensional (2D) co-culture of cells due to the relative ease of use but with limited representation of the invasive growth phenotype, one of the hallmarks of cancer cells. Current three-dimensional (3D) co-culture systems either require special equipment or separate monitoring for invasion of co-cultured cancer cells and interacting T-cells. Here we describe an approach to simultaneously monitor the invasive behavior in 3D of cancer cell spheroids and T-cell cytotoxicity in co-culture. Spheroid formation is driven by enhanced cell-cell interactions in scaffold-free agarose microwell casts with U-shaped bottoms. Both T-cell co-culture and cancer cell invasion into type I collagen matrix are performed within the microwells of the agarose casts without the need to transfer the cells, thus maintaining an intact 3D co-culture system throughout the assay. The collagen matrix can be separated from the agarose cast, allowing for immunofluorescence (IF) staining and for confocal imaging of cells. Also, cells can be isolated for further growth or subjected to analyses such as for gene expression or fluorescence activated cell sorting (FACS). Finally, the 3D co-culture can be analyzed by immunohistochemistry (IHC) after embedding and sectioning. Possible modifications of the assay include altered compositions of the extracellular matrix (ECM) as well as the inclusion of different stromal or immune cells with the cancer cells.

Indexed as

Cell CommunicationCell Line, TumorCoculture TechniquesCollagen Type IExtracellular MatrixHumansNeoplasm InvasivenessSpheroids, CellularT-Lymphocytes, CytotoxicCollagen Type I

Identifiers

PMID32658183
PMCPMC8441943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.